# Evotec wins $74M DOD contract for orthopoxvirus antibodies

Evotec's Just - Evotec Biologics unit received a $74 million contract from the U.S. Department of Defense for rapid development of monoclonal antibodies against mpox, chickenpox and smallpox, from discovery through Phase 1.

- Type: Contract
- Announced: 2023-07-05
- Where: Seattle, United States
- Value: $74.0M
- Status: announced
- Products: monoclonal antibodies against orthopoxviruses
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Evotec AG](https://endata.com/companies/64924.md)
- [U.S. Department of Defense](https://endata.com/companies/4836.md) (customer)

## Sources

- [fiercebiotech.com](https://www.fiercebiotech.com/biotech/evotecs-latest-dod-contract-will-see-biotech-take-74m-tackle-mpox), 2023-07-05: "Evotec has secured yet another contract from the Department of Defense (DOD). This time, the U.S. government is committing $74 million for the development of monoclonal antibodies against mpox, chickenpox and smallpox."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.